Compliance Radar
Who was sanctioned, and for what?
Fines, court rulings and incidents from Europe and North America: 756 cases from 32 jurisdictions, each with an official source and checked against that source before publication. Filter by country, area of law and sector. Click a chart to drill down one level.
Click a bar to drill down one level.
Where?
by regionAll jurisdictions
What for?
by area of lawAll areas of law
Who?
by company- ExxonMobil Chemical Limited 2 cases 8 % · €513,011
- AFCO (Tochtergesellschaft der Zep Inc.) 1 case 4 % · €157,452
- Alkaloids of Australia, Alkaloids Corporation, Boehringer, Linnea, Transo-Pharm (C2 PHARMA Kronzeuge) 1 case 4 % · €13.4m
- Caroline J. Campbell (Beschäftigte der ImmunityBio, Inc.) 1 case 4 % · €288,298
- Colorcon Limited 1 case 4 % · €176,590
- Dompé U.S. Inc. 1 case 4 % · €27.5m
- Estee Lauder Cosmetics Ltd. 1 case 4 % · €463,765
- EyePoint Pharmaceuticals, Inc. 1 case 4 % · €4.08m
- Gilead Sciences, Inc. 1 case 4 % · €177.8m
- Guangxi Kelun Pharmaceutical Co., Ltd. 1 case 4 % ·
- 14 more14 cases
When?
per quarter, by date of decision| Period | Cases | Total |
|---|---|---|
| Q3 2023 | 0 | — |
| Q4 2023 | 0 | — |
| Q1 2024 | 0 | — |
| Q2 2024 | 0 | — |
| Q3 2024 | 0 | — |
| Q4 2024 | 1 | €462.6m |
| Q1 2025 | 0 | — |
| Q2 2025 | 0 | — |
| Q3 2025 | 0 | — |
| Q4 2025 | 0 | — |
| Q1 2026 | 0 | — |
| Q2 2026 | 0 | — |
| Q3 2026 | 0 | — |
1 case
31 Oct 2024 Teva Pharmaceutical Industries (Teva-Gruppe)EU: 462.6 million EUR against Teva for patent misuse and disparaging a competing medicine €462.6m
Teva abused its dominant position for the MS medicine Copaxone: it artificially extended patent protection by filing staggered divisional applications with the EPO and strategically withdrawing them, and spread misleading statements about an authorised competing product among physicians and decision-makers. Seven Member States were affected over periods of four to nine years.
Communications by sales representatives and medical affairs about competing products must be substantiated and objective; patent strategies of dominant companies require competition law review.
Disparaging statements about competing products to healthcare professionals
- Authority / court
- Europäische Kommission
- Area of law
- Competition law · Abuse of market power
- Legal basis
- Art. 102 AEUV
- Action
- Fine
- Status of proceedings
- unknown
- Sector
- Chemicals and pharmaceuticals
- Employees
- 10,000 or more
- Commission fines Teva €462.6 million over misuse of the patent system and disparagement (IP/24/5581) Press release of an authority
Checked against the official source on 25 Sep 2026 · Direct link